Showing results (81-90 of 159) with videos related to

Sort By:
Pageof 16
British Journal of Haematology|May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
American Journal of Clinical Pathology|February 17, 2012
Clinical and pathologic features of secondary acute promyelocytic leukemiaAmy S Duffield, Joseph Aoki, Mark Levis, et al.
Blood|March 31, 2005
Internal tandem duplications of the FLT3 gene are present in leukemia stem cellsMark Levis, Kathleen M Murphy, Rosalyn Pham, et al.
The Journal of Molecular Diagnostics : JMD|April 23, 2003
Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assayKathleen M Murphy, Mark Levis, Michael J Hafez, et al.
Blood|January 17, 2004
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemiaB Douglas Smith, Mark Levis, Miloslav Beran, et al.
Oncotarget|September 26, 2018
Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3Kozo Nagai, Lihong Hou, Li Li, et al.
Leukemia Research|September 14, 2016
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studiesKelly J Norsworthy, Eunpi Cho, Jyoti Arora, et al.
Haematologica|January 28, 2021
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemiaLauren Lee, Yoshiyuki Hizukuri, Paul Severson, et al.
Blood|May 16, 2002
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivoMark Levis, Jeffrey Allebach, Kam-Fai Tse, et al.
The Lancet. Oncology|January 18, 2018
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyCourtney D DiNardo, Keith W Pratz, Anthony Letai, et al.
Pageof 16